Linsitinib is an experimental drug candidate for the treatment of various types of cancer. It is an inhibitor of the

insulin receptor The insulin receptor (IR) is a transmembrane receptor that is activated by insulin, IGF-I, IGF-II and belongs to the large class of receptor tyrosine kinase. Metabolically, the insulin receptor plays a key role in the regulation of glucose ho ...

and of the

insulin-like growth factor 1 receptor The insulin-like growth factor 1 (IGF-1) receptor is a protein found on the surface of human cells. It is a transmembrane receptor that is activated by a hormone called insulin-like growth factor 1 (IGF-1) and by a related hormone called IGF-2. It ...

(IGF-1R). This prevents tumor cell proliferation and induces tumor cell apoptosis. Linsitinib was granted

orphan drug designation An orphan drug is a pharmaceutical agent developed to treat medical conditions which, because they are so rare, would not be profitable to produce without government assistance. The conditions are referred to as orphan diseases. The assignment of ...

for adrenocortical carcinoma in March 2012. Phase II clinical trials were initiated for multiple myeloma, ovarian cancer, hepatocellular carcinoma, and NSCLC, but subsatisfactory results caused research for these indications to be discontinued. A phase III clinical trial found that linsitinib did not increase survival in patients with adrenocortical carcinoma. As of 2017, no clinical trials were in progress.

References

External links

* Experimental cancer drugs Quinolines Protein kinase inhibitors Astellas Pharma Cyclobutanes Imidazopyrazines Antineoplastic drugs {{antineoplastic-drug-stub